RECRUITING

Improve Outcomes for Older Allogeneic Transplant Recipients

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is an interventional pilot study to determine whether implementation of a supervised exercise program can improve outcomes in subjects undergoing allogeneic HCT. The primary objective is to determine feasibility. Up to 60-72 evaluable subjects will be enrolled. Evaluable subjects are defined as those participating in the exercise intervention.

Official Title

Intervening on Frailty to Improve Outcomes for Older Allogeneic Transplant Recipients

Quick Facts

Study Start:2023-02-15
Study Completion:2026-11-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05612789

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Age 60 years or older.
  2. 2. Planned allogeneic HCT in the next 1-6 months.
  3. 3. Hematological malignancy as the indication for HCT.
  4. 4. Pre-frail or frail by Fried frailty phenotype.
  5. 1. Age 60 years or older.
  6. 2. Planned allogeneic HCT or HCT within the last 30 days.
  7. 3. Hematological malignancy as the indication for HCT.
  1. 1. Comorbid disability or illness that prevents safe exercise.

Contacts and Locations

Study Contact

Jacqui Rick
CONTACT
2152209675
Jacqui.Rick@pennmedicine.upenn.edu

Principal Investigator

Shannon McCurdy, MD
PRINCIPAL_INVESTIGATOR
Penn Medicine

Study Locations (Sites)

Penn Medicine
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: Abramson Cancer Center at Penn Medicine

  • Shannon McCurdy, MD, PRINCIPAL_INVESTIGATOR, Penn Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-02-15
Study Completion Date2026-11-01

Study Record Updates

Study Start Date2023-02-15
Study Completion Date2026-11-01

Terms related to this study

Additional Relevant MeSH Terms

  • Allogeneic Transplantation